Merck KGaA (MRCG.DE) News|
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

11:35am EDT
Change (% chg)

€0.69 (+0.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Mon, Jun 20 2016

BRIEF-Merck KGaA says plans to apply for authorization for Avelumab in H2

* Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage:

CORRECTED-BRIEF-Merck KGaA, Pfizer present positive mid-stage data on merkel cell carcinoma drug at ASCO

* Say pivotal avelumab study shows positive results in metastatic merkel cell carcinoma

BRIEF-Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial

* Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage:

BRIEF-Merck KGaA expects to file for first approval of Avelumab in H2

* CEO says expects to file for first approval of Avelumab in merkel cell carcinoma in H2 Further company coverage:

Merck KGaA sees gain in adj EBITDA of up to 18.5 pct

FRANKFURT, May 19 German drugs and chemicals maker Merck KGaA expects adjusted core earnings to increase by up to 18.5 percent this year, helped by additional profit from a takeover of lab supplies maker Sigma-Aldrich.

Germany's Merck says gene editing to help it outperform

DARMSTADT, Germany Germany's Merck KGaA, the world's second-largest supplier of materials and equipment to the biotech sector, expects to continue delivering market-beating sales growth, helped in part by new gene modification techniques.

BRIEF-Merck sees negative FX effects for 2016

* Says sees significant nominal and slight organic growth in sales this year

BRIEF-Merck KGaA selects Unisys to deliver global end-user IT services

* Merck kgaa selects unisys to deliver global end-user it services to support its growth strategy

Select another date: